JGJohn Gatfield

John Gatfield

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John Gatfield has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Discovery of Galactopyranose‐1‐carboxamides as a New Class of Small, Novel, Potent, Selective, and Orally Active Galectin‐3 Inhibitors

    by Cornelia Zumbrunn, Luboš Remen, Christoph P. Sager, Corinna Grisostomi, Christina Stamm, Daniela Krüsi, Sven Glutz, Gunther Schmidt, Oliver Nayler, Marc Iglarz, et al.

    Galectin‐3 (Gal‐3), a β‐galactoside‐binding lectin, is implicated in diverse cellular functions ranging from immune response modulation to tissue homeostasis. Notably, increased Gal‐3 expression has been linked to the progression of numerous diseases, including cancer, fibrosis, and cardiovascular disorders, underscoring its potential as a therapeutic target. Small molecule inhibitors have been discovered and are valuable tools to study such diseases. We report here the discovery of novel, galactose‐based, small molecule inhibitors such as compound 12 which are orally bioavailable and show efficacy in a mouse model of acute liver injury and fibrosis (CCl4 model). The use of structure‐based drug design (docking of a virtual library of amides based on acid 2) was key in the process towards potent, nanomolar inhibitors.


  • Open Access

    A uniquely efficacious type of CFTR corrector with complementary mode of action

    by Valentina Marchesin, Lucile Monnier, Peter Blattmann, Florent Chevillard, Christine Kuntz, Camille Forny, Judith Kamper, Rolf Studer, Alexandre Bossu, Eric A. Ertel, et al.

    Three distinct pharmacological corrector types (I, II, III) with different binding sites and additive behavior only partially rescue the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) folding and trafficking defect observed in cystic fibrosis. We describe uniquely effective, macrocyclic CFTR correctors that were additive to the known corrector types, exerting a complementary “type IV” corrector mechanism. Macrocycles achieved wild-type–like folding efficiency of F508del-CFTR at the endoplasmic reticulum and normalized CFTR currents in reconstituted patient-derived bronchial epithelium. Using photo-activatable macrocycles, docking studies and site-directed mutagenesis a highly probable binding site and pose for type IV correctors was identified in a cavity between lasso helix-1 (Lh1) and transmembrane helix-1 of membrane spanning domain (MSD)-1, distinct from the known corrector binding sites. Since only F508del-CFTR fragments spanning from Lh1 until MSD2 responded to type IV correctors, these likely promote cotranslational assembly of Lh1, MSD1, and MSD2. Previously corrector-resistant CFTR folding mutants were also robustly rescued, suggesting substantial therapeutic potential for type IV correctors.


  • Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure–activity–relationship, and sleep-promoting properties in rats

    by Christine Brotschi, Martin H. Bolli, John Gatfield, Catherine Roch, Thierry Sifferlen, Alexander Treiber, Jodi T. Williams, Christoph Boss

    Selective orexin 2 receptor antagonists (2-SORA) such as seltorexant (15) are in clinical development for the treatment of insomnia and other conditions such as depression. Herein, we report our structure–activity–relationship (SAR) optimization efforts starting from an HTS hit (1) (N-(1-((5-acetylfuran-2-yl)methyl)-1H-pyrazol-4-yl)-5-(m-tolyl)oxazole-4-carboxamide) that was derived from an unrelated in-house GPCR-agonist program. Medicinal chemistry efforts focused on the optimization of orexin 2 receptor (OX2R) antagonistic activity, stability in liver microsomes, time dependent CYP3A4 inhibition, and aqueous solubility. Compounds were assessed for their brain-penetrating potential in in vivo experiments to select the most promising compounds for our in vivo sleep model. Our lead optimization efforts led to the discovery of the potent, brain penetrating and orally active, 2-SORA (N-(1-(2-(5-methoxy-1H-pyrrolo[3,2-b]pyridin-3-yl)ethyl)-1H-pyrazol-4-yl)-5-(m-tolyl)oxazole-4-carboxamide) 43 with efficacy in a sleep model in rats comparable to 15.


  • Open Access

    A Novel, Uniquely Efficacious Type of CFTR Corrector with Complementary Mode of Action

    by Valentina Marchesin, Lucile Monnier, Peter Blattmann, Florent Chevillard, Christine Kuntz, Camille Forny, Judith Kamper, Rolf Studer, Alexandre Bossu, Eric A. Ertel, et al.

    Three distinct pharmacological corrector types (I, II, III) with different binding sites and additive behaviour only partially rescue the F508del-CFTR folding and trafficking defect observed in cystic fibrosis. Here, we describe novel, uniquely effective, macrocyclic CFTR correctors that were additive to the known corrector types, thus exerting a new, complementary “type-IV” corrector mechanism. Macrocycles achieved wildtype-like folding efficiency of F508del-CFTR at the endoplasmic reticulum and normalized CFTR currents in reconstituted patient-derived bronchial epithelium. Using photo-activatable macrocycles, docking studies and site-directed mutagenesis a highly probable binding site and pose for type-IV correctors was identified in a cavity between lasso helix-1 (Lh1) and transmembrane helix-1 of membrane spanning domain-1 (MSD1), distinct from the known corrector binding sites. Since only F508del-CFTR fragments spanning from Lh1 until MSD2 responded to type-IV correctors, these likely promote co-translational assembly of Lh1, MSD1, and MSD2. Remarkably, previously corrector-resistant CFTR folding mutations were also robustly rescued, suggesting substantial therapeutic potential for this novel type-IV corrector mechanism. Teaser: A novel type of macrocyclic CFTR corrector with new binding site, complementary mode of action and unique folding / trafficking efficacy is described.

  • Open Access

    GPCR-induced YAP activation sensitizes fibroblasts to profibrotic activity of TGFβ1

    by Katarina Zmajkovicova, Yasmina Bauer, Katalin Menyhart, Marie Schnoebelen, Diego Freti, Maxime Boucher, Bérengère Renault, Rolf Studer, Magdalena Birker-Robaczewska, Axel Klenk, et al.

    Tissue fibrosis is a pathological condition characterized by uncontrolled fibroblast activation that ultimately leads to organ failure. The TGFβ1 pathway, one of the major players in establishment of the disease phenotype, is dependent on the transcriptional co-activators YAP/TAZ. We were interested whether fibroblasts can be sensitized to TGFβ1 by activation of the GPCR/YAP/TAZ axis and whether this mechanism explains the profibrotic properties of diverse GPCR ligands. We found that LPA, S1P and thrombin cooperate in human dermal fibroblasts with TGFβ1 to induce extracellular matrix synthesis, myofibroblast marker expression and cytokine secretion. Whole genome expression profiling identified a YAP/TAZ signature behind the synergistic profibrotic effects of LPA and TGFβ1. LPA, S1P and thrombin stimulation led to activation of the Rho-YAP axis, an increase of nuclear YAP-Smad2 complexes and enhanced expression of profibrotic YAP/Smad2-target genes. More generally, dermal, cardiac and lung fibroblast responses to TGFβ1 could be enhanced by increasing YAP nuclear levels (with GPCR ligands LPA, S1P, thrombin or Rho activator) and inhibited by decreasing nuclear YAP (with Rho inhibitor, forskolin, latrunculin B or 2-deoxy-glucose). Thus, we present here a conceptually interesting finding that fibroblast responses to TGFβ1 can be predicted based on the nuclear levels of YAP and modulated by stimuli/treatments that change YAP nuclear levels. Our study contributes to better understanding of fibrosis as a complex interplay of signalling pathways and proposes YAP/TAZ as promising targets in the treatment of fibrosis.


  • From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs

    by Christine Brotschi, Martin H. Bolli, John Gatfield, Bibia Heidmann, Francois Jenck, Catherine Roch, Thierry Sifferlen, Alexander Treiber, Jodi T. Williams, Christoph Boss

    The orexin system is responsible for regulating the sleep‐wake cycle. Suvorexant, a dual orexin receptor antagonist (DORA) is approved by the FDA for the treatment of insomnia disorders. Herein, we report the optimization efforts toward a DORA, where our starting point was (5‐methoxy‐4‐methyl‐2‐[1,2,3]triazol‐2‐yl‐phenyl)‐{(S)‐2‐[5‐(2‐trifluoromethoxy‐phenyl)‐[1,2,4]oxadiazol‐3‐yl]‐pyrrolidin‐1‐yl}methanone (6), a compound which emerged from our in‐house research program. Compound 6 was shown to be a potent, brain‐penetrating DORA with in vivo efficacy similar to suvorexant in rats. However, shortcomings from low metabolic stability, high plasma protein binding (PPB), low brain free fraction (fu brain), and low aqueous solubility, were identified and hence, compound 6 was not an ideal candidate for further development. Our optimization efforts addressing the above‐mentioned shortcomings resulted in the identification of (4‐chloro‐2‐[1,2,3]triazol‐2‐yl‐phenyl)‐{(S)‐2‐methyl‐2‐[5‐(2‐trifluoromethoxy‐phenyl)‐4H‐[1,2,4]triazol‐3‐yl]‐pyrrolidin‐1‐yl}l‐methanone (42), a DORA with improved in vivo efficacy compared to 6.


  • Open Access

    Predictive Power of Time-Series Based Machine Learning Models for DMPK Measurements in Drug Discovery

    by Modest von Korff, Olivier Corminboeuf, John Gatfield, Sébastien Jeay, Isabelle Reymond, Thomas Sander

    Four datasets measuring DMPK (drug metabolism and pharmacokinetics) parameters, and one target protein-specific dataset were analyzed by machine learning methods. Parameters measured for the five compound sets were biological activity data, plasma protein binding, permeability in MDCK I cell layers, intrinsic clearance by human liver microsomes, and plasma exposure in orally dosed rats. The measured data were sorted chronologically, reflecting the order in which they had been obtained in the discovery project. Subsets of the chronologically sorted data that appeared early in the project were used as training datasets to build predictive models for subsequent compounds based on kNN, partial least squares regression (PLSR), nonlinear PLSR, random forest regression, and support vector regression. A median model was used as a baseline to assess the machine learning model prediction quality. Data sets sorted in order of increasing test set prediction error: intrinsic clearance, plasma protein binding, cell layer permeability, biological activity on target protein, and bioavailability as AUC in rats. Our results give a first estimation of the power of machine learning to predict DMPK properties of compounds in an ongoing drug discovery project.


  • Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers

    by Dorte Renneberg, Francis Hubler, Markus Rey, Patrick Hess, Stephane Delahaye, John Gatfield, Marc Iglarz, Kurt Hilpert